JP2003528913A - アルツハイマー病に伴う神経精神的行動の処置のためのガランタミンの使用 - Google Patents

アルツハイマー病に伴う神経精神的行動の処置のためのガランタミンの使用

Info

Publication number
JP2003528913A
JP2003528913A JP2001572084A JP2001572084A JP2003528913A JP 2003528913 A JP2003528913 A JP 2003528913A JP 2001572084 A JP2001572084 A JP 2001572084A JP 2001572084 A JP2001572084 A JP 2001572084A JP 2003528913 A JP2003528913 A JP 2003528913A
Authority
JP
Japan
Prior art keywords
day
galantamine
dose
weeks
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001572084A
Other languages
English (en)
Japanese (ja)
Inventor
パリ，ビム・ルイ・ジユリアン
ポンテコルボ，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of JP2003528913A publication Critical patent/JP2003528913A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2001572084A 2000-04-03 2001-03-28 アルツハイマー病に伴う神経精神的行動の処置のためのガランタミンの使用 Withdrawn JP2003528913A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
US60/194,259 2000-04-03
PCT/EP2001/003553 WO2001074339A2 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Publications (1)

Publication Number Publication Date
JP2003528913A true JP2003528913A (ja) 2003-09-30

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001572084A Withdrawn JP2003528913A (ja) 2000-04-03 2001-03-28 アルツハイマー病に伴う神経精神的行動の処置のためのガランタミンの使用

Country Status (20)

Country Link
EP (1) EP1272192A2 (no)
JP (1) JP2003528913A (no)
KR (1) KR20020086911A (no)
CN (1) CN1430514A (no)
AU (2) AU2001265844B2 (no)
BG (1) BG107093A (no)
BR (1) BR0109770A (no)
CA (1) CA2310926C (no)
CZ (1) CZ20023543A3 (no)
EE (1) EE200200554A (no)
HR (1) HRP20020778A2 (no)
HU (1) HUP0300566A3 (no)
IL (1) IL152061A0 (no)
MX (1) MXPA02009777A (no)
NO (1) NO20024746L (no)
PL (1) PL361272A1 (no)
RU (1) RU2002129298A (no)
SK (1) SK15422002A3 (no)
WO (1) WO2001074339A2 (no)
ZA (1) ZA200207935B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
EP1651234B1 (en) 2003-07-25 2007-09-26 F. Hoffmann-La Roche Ag Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
ES2634421T3 (es) 2008-03-27 2017-09-27 Chase Pharmaceuticals Corporation Uso y composición para tratar la demencia
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (bg) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
CA2986431C (en) * 2015-05-18 2020-04-14 Synaptec Development Llc Galantamine clearance of amyloid.beta.
CN117957003A (zh) * 2021-09-09 2024-04-30 上海日馨医药科技股份有限公司 治疗神经退行性疾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
WO2000030446A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
CA2358062C (en) * 1998-12-24 2006-12-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects

Also Published As

Publication number Publication date
IL152061A0 (en) 2003-05-29
HUP0300566A2 (hu) 2003-06-28
AU2001265844B2 (en) 2005-04-14
CN1430514A (zh) 2003-07-16
CA2310926A1 (en) 2000-10-04
WO2001074339A2 (en) 2001-10-11
EP1272192A2 (en) 2003-01-08
WO2001074339A3 (en) 2002-09-12
KR20020086911A (ko) 2002-11-20
AU6584401A (en) 2001-10-15
HUP0300566A3 (en) 2004-10-28
RU2002129298A (ru) 2004-03-27
CA2310926C (en) 2002-10-15
PL361272A1 (en) 2004-10-04
CZ20023543A3 (cs) 2003-03-12
SK15422002A3 (sk) 2003-04-01
ZA200207935B (en) 2004-01-30
BG107093A (bg) 2003-06-30
BR0109770A (pt) 2003-02-04
NO20024746D0 (no) 2002-10-02
NO20024746L (no) 2002-11-28
MXPA02009777A (es) 2003-03-27
HRP20020778A2 (en) 2004-04-30
EE200200554A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
Kantor et al. Oral analgesic studies: pentazocine hydrochloride, codeine, aspirin, and placebo and their influence on response to placebo
US20240075021A1 (en) Use of pridopidine for treating dystonias
JPH02500975A (ja) コリン作動性ニューロン欠損状態でのモノアミンアクリジン類の投与
JP2010510314A (ja) 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
JP2004513874A (ja) 副作用を軽減する効果的なガランタミンの投薬計画
US20230115839A1 (en) Methods For Treating Hypersomnia
JP2003528913A (ja) アルツハイマー病に伴う神経精神的行動の処置のためのガランタミンの使用
Bachert et al. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis
AU2001265844A1 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
KR101442295B1 (ko) 실로스타졸을 포함하는 통합 실조증 치료제
US20060172993A1 (en) Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease
M Farber et al. Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson’s disease
TW202031250A (zh) 用於治療負性症狀和認知損傷之pde10a抑制劑
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
Schifano Drug abuse: treatment and management
Panas et al. Belladonna alkaloids and phenobarbital use in the treatment of irritable bowel syndrome: a review
Wade et al. First impressions of the use of meptazinol in general practice
AU2020398082A1 (en) Treating behavioral and psychological symptoms in dementia patients
CN102548550A (zh) 外型-s-美卡拉明用于治疗的方法、用途和化合物
SELZER et al. The use of doxylamine in schizophrenia: pitfalls in the evaluation of a new drug
EA045669B1 (ru) Способы лечения поведенческих и психологических симптомов у пациентов с деменцией
WO2020094592A1 (en) Compounds for treating negative symptoms and cognitive impairments
Homma et al. Recent clinical trials of cholinomimetics for patients with Alzheimer’s Disease in Japan
Simone Medical Consequences of Over-the-Counter (OTC) Substance Abuse
Chlor-Tripolon 74¢ only My téafa

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080202

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20080603